[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Atrium Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":59},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":4},"100649725","phase-1-atr-1072-in-participants-with-prkag2-syndrome-100649725",false,"NCT07738107","ATR 1072 in Participants With PRKAG2 Syndrome","A Phase 1\u002F2, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous ATR 1072 for the Treatment of PRKAG2 Syndrome","Inclusion Criteria:\n\n1. Adults 18 to 65 years of age.\n2. Pathogenic, likely pathogenic, or variant of uncertain significance (VUS) in PRKAG2 confirmed by genetic testing.\n3. Clinical manifestations consistent with PRKAG2 Syndrome.\n4. Able and willing to comply with study procedures.\n5. Able and willing to undergo endomyocardial biopsy procedures (Part A)\n\nExclusion Criteria:\n\n1. Pregnancy or breastfeeding.\n2. Significant hepatic, renal, hematologic, or cardiovascular abnormalities that may increase study risk.\n3. NYHA Class IV heart failure or left ventricular ejection fraction \\\u003C45%.\n4. Recent clinically significant cardiovascular events or procedures.\n5. Prior treatment with prohibited investigational therapies or oligonucleotide therapies within protocol-defined washout periods.\n6. Any condition that, in the investigator's","ALL","18 Years","65 Years",{"count":20,"type":21},37,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","ATR 1072 is an investigational medicine being studied in adults with PRKAG2 Syndrome. This study will evaluate the safety of ATR 1072 and how the body processes the drug. Researchers will also assess how ATR 1072 affects PRKAG2 activity and measures of heart disease.",[28,29,30,31],"Cardiac Glycogenosis","Cardiomyopathy","Hypertrophic","Wolff-Parkinson-White Syndrome",[33,34,35,36,37,38,39,40,41,42,43,44,45,46],"AMPK","TfR1","transferrin receptor","ATR 1072","targeted RNA delivery","siRNA","antibody-oligonucleotide conjugate (AOC)","glycogen storage disease","PRKAG2 Syndrome","cardiac glycogenosis","cardiomyopathy","PRKAG2","genetic cardiomyopathy","corventis","NOT_YET_RECRUITING","2026-07-28",{"date":50,"type":51},"2026-07-31","ACTUAL",{"date":53,"type":21},"2026-10",{"date":55,"type":21},"2028-10",{"name":57,"class":58},"Atrium Therapeutics","INDUSTRY",""]